# To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets

> **NCT00946608** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 30 (actual)

## Conditions studied

- Allergy

## Interventions

- **DRUG:** Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
- **DRUG:** Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
- **DRUG:** Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)

## Key facts

- **NCT ID:** NCT00946608
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946608, "To Demonstrate the Relative Bioavailability Study of Loratadine 10 mg Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00946608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*